| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/16/2002 | WO2001032685A8 Gene expression directed by a super-psa promoter |
| 05/16/2002 | WO2001032128A9 Human chemokine beta-13 |
| 05/16/2002 | WO2001007434A3 Indole derivatives and their use as 5ht2a ligands |
| 05/16/2002 | US20020059652 Detecting modulators of liver cell propagation, cell differentiation and lymphocyte activity; obtain modulator, incubate with indicator, mix with culture monitor culture for adjustment in activity |
| 05/16/2002 | US20020058839 Methods and compositions for modulating alpha adrenergic receptor activity |
| 05/16/2002 | US20020058710 For therapy and prophylaxis of arrhythmias, cardiac infraction, ischemic conditions, angina pectoris, shock, for preserving and storing a transplant for surgical measure |
| 05/16/2002 | US20020058709 For therapy and prophylaxis of allergic disease of the eye, nose, skin, ear, gastrointestinal tract or lungs |
| 05/16/2002 | US20020058700 Ion channel modulating agents |
| 05/16/2002 | US20020058690 For therapy and prophylaxis of inflammatory disease susceptible to treatment with a non- steroidal anti-inflammatory agent |
| 05/16/2002 | US20020058686 Administering of angiotensin II receptor antagonist for therapy of angina |
| 05/16/2002 | US20020058685 Hydantoin derivative compounds, pharmace utical compositions, and methods of using same |
| 05/16/2002 | US20020058672 Use of benzoylalkyl-1,2,3,6-tetrahydropyridines |
| 05/16/2002 | US20020058665 For use in cancer therapy |
| 05/16/2002 | US20020058654 For therapy of uterine fibroids, endometriosis, polycystic ovarian disease, dysfunctional uterine bleeding, breast cancer and ovarian cancer; depletion of oocytes; spermatocyte depletion; for female and male contraception |
| 05/16/2002 | US20020058651 Estra-1,3,5(10), 16-tetraene derivatives |
| 05/16/2002 | US20020058644 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/16/2002 | US20020058638 Decreasing blood glucose levels, inhibiting PEPCK expression, decreasing blood insulin levels, decreasing insulin resistance, increasing insulin sensitivity, decreasing blood triglyceride levels or decreasing blood cholesterol levels |
| 05/16/2002 | US20020058636 Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
| 05/16/2002 | US20020058635 Purine L-nucleosides, analogs and uses thereof |
| 05/16/2002 | US20020058631 Dipeptide derivatives |
| 05/16/2002 | US20020058630 Urea heterocycliccarbonyl-substituted aspartic or glutamic acid derivatives |
| 05/16/2002 | US20020058619 Ligand for vascular endothelial growth factor receptor |
| 05/16/2002 | US20020058611 Therapeutic agent is conjugated to the carrier via a biodegradable disulfide bond. |
| 05/16/2002 | US20020058607 Containing the amino acid sequence (G/S/A/E)-L-F-(F/I/L); each - is a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, and each slash separating the alternative amino acids. |
| 05/16/2002 | US20020058284 Methods and compositions for treating macrophage-mediated diseases |
| 05/16/2002 | US20020058267 Nucleotide sequences coding polypeptide for use in the treatment of alzheimer's disease |
| 05/16/2002 | US20020058078 Incubating acidified vegetation water from olives for at least two months, until at least 75% of oleoeuropein originally present in the vegetation water has been converted to hydroxytyrosol. |
| 05/16/2002 | US20020058066 Outer layer portion containing cilostazol, a water-insoluble substance, such as ethyl cellulose, and a hydrophilic hydrogel forming substance, such as hydroxypropyl methyl cellulose. |
| 05/16/2002 | US20020058036 Novel fibroblast growth factor and nucleic acids encoding same |
| 05/16/2002 | US20020058035 Reducing FSH levels by administering a GnRH antagonist to reduce both plasma FSH and LH levels; treating prostatic intraepithelial neoplasia, pedophilia, infertility, vaginal bleeding; in vitro fertilization and male contraception |
| 05/16/2002 | US20020058029 Anti-CD40L, anti-B7.1 (CD80), anti-B7.2(CD86), CD40 antibody or anti-CD4 antibody; both may be administered separately or in combination, and in any order. |
| 05/16/2002 | US20020058025 Stromal cell use |
| 05/16/2002 | US20020058023 Apoptotic bodies and/or apoptotic cells are in a liquid suspension along with viable cells. |
| 05/16/2002 | US20020058022 Novel compounds |
| 05/16/2002 | CA2428492A1 Method for screening agents by modulating the expression of sparc |
| 05/16/2002 | CA2428318A1 Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect |
| 05/16/2002 | CA2428266A1 Substituted alkyldiamines as inhibitors of plasmepsin or related proteases |
| 05/16/2002 | CA2428241A1 Novel human potassium channel beta subunit |
| 05/16/2002 | CA2428204A1 Lipid peroxide-lowering compositions |
| 05/16/2002 | CA2428176A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 05/16/2002 | CA2428164A1 Method for the treatment of inflammation |
| 05/16/2002 | CA2428117A1 Immunogenic compositions comprising liver stage malarial antigens |
| 05/16/2002 | CA2427757A1 Therapeutic uses for ip3 receptor-mediated calcium channel modulators |
| 05/16/2002 | CA2427350A1 Pyrimidine derivatives and their use as neuropeptide y receptor ligands |
| 05/16/2002 | CA2426730A1 Calcilytic compounds |
| 05/16/2002 | CA2426508A1 Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states |
| 05/16/2002 | CA2426049A1 Improved treatment |
| 05/16/2002 | CA2425829A1 Proteases |
| 05/16/2002 | CA2421594A1 3-substituted oxindole beta 3 agonists |
| 05/16/2002 | CA2421154A1 Peroxisome proliferator activated receptor alpha agonists |
| 05/15/2002 | EP1205478A1 p38MAP KINASE INHIBITORS |
| 05/15/2002 | EP1205185A1 Uterine contraction inhibitors |
| 05/15/2002 | EP1205178A2 Conjugate, method for its production and use thereof |
| 05/15/2002 | EP1204745A2 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| 05/15/2002 | EP1204744A1 Isolated peptide of the horny layer and use thereof |
| 05/15/2002 | EP1204742A2 Oligonucleotides for inhibiting the expression of human eg5 |
| 05/15/2002 | EP1204681A2 Helical cytokine zalpha48 |
| 05/15/2002 | EP1204675A1 Streptogramin derivatives, production thereof and compositions containing the same |
| 05/15/2002 | EP1204665A2 Chemokine receptor antagonists and methods of use therefor |
| 05/15/2002 | EP1204662A1 Azaindoles having serotonin receptor affinity |
| 05/15/2002 | EP1204659A2 Serotonergic benzofurans |
| 05/15/2002 | EP1204658A1 Benzofurylpiperazine serotonin agonists |
| 05/15/2002 | EP1204657A1 Piperidine and pyrrolidine derivatives displaying neuronal activity |
| 05/15/2002 | EP1204656A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride |
| 05/15/2002 | EP1204654A1 Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
| 05/15/2002 | EP1204652A1 Novel succinate derivative compounds useful as cysteine protease inhibitors |
| 05/15/2002 | EP1204646A1 1,4,5,6 -tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 05/15/2002 | EP1204645A2 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 05/15/2002 | EP1204641A1 4-aminopiperidine derivatives of tetrahydronaphthalene, chromans and thiochromans |
| 05/15/2002 | EP1204626A1 Ether compounds, compositions, and uses thereof |
| 05/15/2002 | EP1204430A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 05/15/2002 | EP1204419A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 05/15/2002 | EP1204414A2 Use of morphinan derivates as medicines |
| 05/15/2002 | EP1204411A1 Apicidin-derived cyclic tetrapeptides |
| 05/15/2002 | EP1167360A9 Human chymase inhibitors |
| 05/15/2002 | EP1096941A4 Bone marrow cells as a source of neurons for brain and spinal cord repair |
| 05/15/2002 | EP1071745A4 Process for synthesizing cox-2 inhibitors |
| 05/15/2002 | EP1049694B1 Derivatives of benzoxadiazoles, benzothiadiazoles, benzotriazoles and quinoxalines |
| 05/15/2002 | EP0923549B1 Methanesulphonate salt of an arylpiperazine derived from tryptamine and its solvates for pharmaceutical use |
| 05/15/2002 | EP0883622B1 Proton pump inhibitor |
| 05/15/2002 | EP0792163B1 Acne treating-wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids |
| 05/15/2002 | EP0778833B1 Endothelin receptor antagonists |
| 05/15/2002 | EP0706513B1 Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| 05/15/2002 | CN1349542A Heterocyclic compounds, intermediates thereof and elastase inhibitors |
| 05/15/2002 | CN1349538A Cyclocarbamate and cyclic amide derivatives |
| 05/15/2002 | CN1349534A 6-alkenyl-, 6-alkinyl-and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
| 05/15/2002 | CN1349531A Cyanopyrroles as progesterone receptor agonists |
| 05/15/2002 | CN1349530A 1-(P-thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds |
| 05/15/2002 | CN1349528A Pyrimidine compounds |
| 05/15/2002 | CN1349526A Prodrugs of thrombin inhibitors |
| 05/15/2002 | CN1349524A Renin inhibitors |
| 05/15/2002 | CN1349523A Novel lipoic acid derivatives, their prepn., and pharmaceutical compositions containing them |
| 05/15/2002 | CN1349521A Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 05/15/2002 | CN1349519A Glucokinase activators |
| 05/15/2002 | CN1349517A Cyclocarbamate derivatives as progesterone receptor modulators |
| 05/15/2002 | CN1349516A Cyclothiocarbamate derivatives as progesterone receptor modulators |
| 05/15/2002 | CN1349511A Benzimidazolrone and analogues, and the use as ligand of progesterone |
| 05/15/2002 | CN1349510A Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors |
| 05/15/2002 | CN1349509A Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 05/15/2002 | CN1349508A Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |